# Nuclide record sortilin (target). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/targets/sortilin/>
  a schema:BioChemEntity ;
  nuclide:kind "target" ;
  schema:identifier "sortilin" ;
  schema:name "Sortilin (SORT1)"@en ;
  schema:alternateName "SORT1"@en, "Neurotensin receptor 3"@en, "NTSR3"@en, "Gp95"@en, "SORT1" ;
  schema:description "A receptor that pulls molecules into cells and is found at high levels in several cancers, including ovarian, endometrial and triple-negative breast cancer. A peptide-drug conjugate against it is in a phase 1 trial, and the first radioactive pair (one version for scans, one for treatment) was published in 2026."@en ;
  schema:url <https://nuclide.cc/targets/sortilin/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11186>, <https://pubmed.ncbi.nlm.nih.gov/41773941/>, <https://pubmed.ncbi.nlm.nih.gov/35454785/>, <https://pubmed.ncbi.nlm.nih.gov/34314556/>, <https://clinicaltrials.gov/study/NCT04706962> ;
  nuclide:tag "internalising receptor", "peptide-drug conjugate", "theranostic pair" ;
  nuclide:targetClass "surface-antigen" ;
  nuclide:related <https://nuclide.cc/technologies/peptide-drug-conjugate/>, <https://nuclide.cc/isotopes/zr-89/>, <https://nuclide.cc/isotopes/lu-177/>, <https://nuclide.cc/technologies/immuno-pet/>, <https://nuclide.cc/technologies/radioimmunotherapy/>, <https://nuclide.cc/indications/breast-triple-negative/> ;
  nuclide:indications <https://nuclide.cc/indications/breast-triple-negative/> .